Search
Technetium Tc-99m succimer
go.drugbank.com/drugs/DB09436Approved[L40558] The use of technetium Tc-99m succimer for the detection of kidney cortical defects was first approved by the FDA on February 23, 2022, under the market name NephroScan.[L40573]
Ethosuximide
go.drugbank.com/drugs/DB00593ApprovedInvestigationalAn anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
Etidronic acid
go.drugbank.com/drugs/DB01077ApprovedInvestigationalEtidronic acid is a first generation bisphosphonate similar to clodronic acid and tiludronic acid. These drugs were developed to mimic the action of pyrophosphate, a regulator of calcification and decalcification. Etidronate’s use has de...
Categories: Drugs for Treatment of Bone DiseasesThyroid, porcine
go.drugbank.com/drugs/DB09100ApprovedInvestigational[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891[A190807] but its use dates back as far as the 6th century.
Dyphylline
go.drugbank.com/drugs/DB00651ApprovedWithdrawnDyphylline is a theophylline derivative with broncho- and vasodilator properties. It is typically used in the management of asthma, cardiac dyspnea, and bronchitis.
Categories: Drugs for Obstructive Airway DiseasesRecombinant Bacterial ACE2 Receptors-like Enzyme
go.drugbank.com/drugs/DB15741InvestigationalIt is being investigated for treating hypertension, myocardial fibrosis, and cardiac dysfunction.
Virus Specific T-Cell
go.drugbank.com/drugs/DB15735InvestigationalVirus Specific T-Cells (VSTs) are a target therapy that are generated for specific viral antigens. These products are generated from virus-naive or virus-experienced autologous or allogenic sources.
Sulfaphenazole
go.drugbank.com/drugs/DB06729ApprovedSulfaphenazole is a sulfonamide antibacterial.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseTafasitamab
go.drugbank.com/drugs/DB15044ApprovedInvestigationalTafasitamab is a humanized, CD19-directed cytolytic monoclonal antibody intended for the treatment of B-cell malignancies. … L15292] Having previously received Breakthrough Therapy, Fast Track, and Orphan designations from the FDA,[A191829] tafasatimab-cxix (Monjuvi®) received an accelerated approval on July 31st, 2020, for
Zinc cation
go.drugbank.com/drugs/DB14532InvestigationalMixtures: Orajel 4X Medicated For Toothache and Gum, Orajel 3X Medicated For Toothache and Gum